Teva gains after FDA approves monthly schizophrenia injection
09/10/2026 16:12
BUZZ-Teva gains after FDA approves monthly schizophrenia injection ** US-listed shares of Israel-based Teva Pharmaceutical Industries TEVA.TA, TEVA.N rise 5.8% to $41.52
** Drugmaker says the US FDA approved Weltruza, a once-monthly injection for adults with schizophrenia
** Teva expects to launch the drug in the United States in the coming weeks
** French biotech Medincell MEDCL.PA may receive up to $112 mln in additional development and commercial milestone payments, plus royalties on sales, under its agreement with Teva
** Including session moves, TEVA has been up 3.9% so far
(Reporting by Siddhi Mahatole)
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris